Wedbush Remains a Buy on Clearside Biomedical (CLSD)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Clearside Biomedical (CLSDResearch Report), with a price target of $18.00. The company’s shares closed last Tuesday at $6.40.

According to, Moussatos is a 3-star analyst with an average return of 3.3% and a 38.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Clearside Biomedical with a $12.67 average price target, representing a 99.8% upside. In a report issued on September 13, JMP Securities also reiterated a Buy rating on the stock with a $10.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.73 and a one-year low of $1.25. Currently, Clearside Biomedical has an average volume of 1.03M.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.